DE60037726D1 - Carbonsäurederivate die die bindung von integrinen an ihre rezeptoren hemmen - Google Patents

Carbonsäurederivate die die bindung von integrinen an ihre rezeptoren hemmen

Info

Publication number
DE60037726D1
DE60037726D1 DE60037726T DE60037726T DE60037726D1 DE 60037726 D1 DE60037726 D1 DE 60037726D1 DE 60037726 T DE60037726 T DE 60037726T DE 60037726 T DE60037726 T DE 60037726T DE 60037726 D1 DE60037726 D1 DE 60037726D1
Authority
DE
Germany
Prior art keywords
binding
receptors
integrines
restrict
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60037726T
Other languages
English (en)
Other versions
DE60037726T2 (de
Inventor
Ronald J Biediger
Qi Chen
George W Holland
Jamal M Kassir
Wen Li
Robert V Market
Ian L Scott
Chengde Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Encysive Pharmaceuticals Inc
Original Assignee
Encysive Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Encysive Pharmaceuticals Inc filed Critical Encysive Pharmaceuticals Inc
Publication of DE60037726D1 publication Critical patent/DE60037726D1/de
Application granted granted Critical
Publication of DE60037726T2 publication Critical patent/DE60037726T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE60037726T 1999-05-07 2000-05-05 Carbonsäurederivate die die bindung von integrinen an ihre rezeptoren hemmen Expired - Lifetime DE60037726T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13297199P 1999-05-07 1999-05-07
US132971P 1999-05-07
PCT/US2000/012303 WO2000067746A1 (en) 1999-05-07 2000-05-05 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors

Publications (2)

Publication Number Publication Date
DE60037726D1 true DE60037726D1 (de) 2008-02-21
DE60037726T2 DE60037726T2 (de) 2009-03-05

Family

ID=22456441

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60037726T Expired - Lifetime DE60037726T2 (de) 1999-05-07 2000-05-05 Carbonsäurederivate die die bindung von integrinen an ihre rezeptoren hemmen

Country Status (23)

Country Link
EP (1) EP1176956B1 (de)
JP (1) JP5132855B2 (de)
AT (1) ATE383153T1 (de)
AU (1) AU5267900A (de)
CA (1) CA2373360C (de)
CY (1) CY1107438T1 (de)
CZ (1) CZ303312B6 (de)
DE (1) DE60037726T2 (de)
DK (1) DK1176956T3 (de)
ES (1) ES2296625T3 (de)
IL (2) IL146311A0 (de)
IN (1) IN2001KN01110A (de)
MX (1) MXPA01011340A (de)
NO (1) NO324421B1 (de)
NZ (1) NZ515248A (de)
PL (1) PL205322B1 (de)
RO (1) RO122246B1 (de)
RU (1) RU2263109C2 (de)
SI (1) SI20744B (de)
SK (1) SK286696B6 (de)
TR (2) TR200103178T2 (de)
WO (1) WO2000067746A1 (de)
ZA (1) ZA200108774B (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6972296B2 (en) 1999-05-07 2005-12-06 Encysive Pharmaceuticals Inc. Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
US6723711B2 (en) * 1999-05-07 2004-04-20 Texas Biotechnology Corporation Propanoic acid derivatives that inhibit the binding of integrins to their receptors
AR026748A1 (es) 1999-12-08 2003-02-26 Vertex Pharma Un compuesto inhibidor de caspasas, una composicion farmaceutica que lo comprende, un metodo para la sintesis del mismo y un compuesto intermediario paradicha sintesis
ES2200617B1 (es) 2001-01-19 2005-05-01 Almirall Prodesfarma, S.A. Derivados de urea como antagonistas de integrinas alfa 4.
SI21096B (sl) * 2001-10-09 2012-05-31 Encysive Pharmaceuticals Inc Derivati karboksilne kisline ki inhibirajo vezavo integrinov na njihove receptorje
ES2334990T3 (es) * 2002-02-14 2010-03-18 Pharmacia Corporation Piridinonas sustituidas como moduladores de p38 map quinasa.
JP4616643B2 (ja) 2002-06-28 2011-01-19 バーテックス ファーマシューティカルズ インコーポレイテッド カスパーゼインヒビターおよびそれらの用途
CN1703395A (zh) 2002-08-09 2005-11-30 特兰斯泰克制药公司 芳基和杂芳基化合物以及调节凝血的方法
TW200505861A (en) * 2002-11-08 2005-02-16 Encysive Pharmaceuticals Inc Combination products with carboxylic acid derivatives that inhibit the binding of integrins to their receptors and other therapeutic compounds
EP1581501A1 (de) 2002-12-20 2005-10-05 Vertex Pharmaceuticals Incorporated 4-oxo-3-(1-oxo-1h-isochinolin-2-ylacetylamino)pentansäureester-und -amidderivate und deren verwendung als caspaseinhibitoren
PE20050159A1 (es) 2003-05-27 2005-04-19 Vertex Pharma Derivados de acido 3-[2-(3-amino-2-oxo-2h-piridin-1-il)-acetilamino]-4-oxo-pentanoico como inhibidores de caspasa
US7208601B2 (en) 2003-08-08 2007-04-24 Mjalli Adnan M M Aryl and heteroaryl compounds, compositions, and methods of use
CA2531796A1 (en) 2003-08-08 2005-02-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions, and methods of use
US7501538B2 (en) 2003-08-08 2009-03-10 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions and methods of use
US9296697B2 (en) 2005-08-24 2016-03-29 Abbott Laboratories Hetaryl-substituted guanidine compounds and use thereof as binding partners for 5-HT5-receptors
US8410150B2 (en) 2007-03-09 2013-04-02 University Health Network Inhibitors of carnitine palmitoyltransferase and treating cancer
CA2677049A1 (en) 2007-08-01 2009-02-05 Sionex Corporation Cyclic inhibitors of carnitine palmitoyltransferase and treating cancer
MX2011011326A (es) * 2009-04-27 2012-02-13 Elan Pharm Inc Antagonistas de piridinona de las integrinas alfa-4.
WO2012033548A2 (en) * 2010-09-07 2012-03-15 E. I. Du Pont De Nemours And Company Herbicidal bis-nitrogen-containing oxo and sulfono heterocycles
CA2771588C (en) 2009-09-09 2018-07-31 E I Du Pont De Nemours And Company Herbicidal pyrimidone derivatives
EP2810937B1 (de) * 2012-01-31 2016-11-30 Daiichi Sankyo Company, Limited Pyridonderivat
TWI690511B (zh) 2013-09-20 2020-04-11 美商拜奧馬林製藥公司 用於治療疾病之葡萄糖苷基腦醯胺（ｇｌｕｃｏｓｙｌｃｅｒａｍｉｄｅ）合成酶抑制劑
JP2017510627A (ja) 2014-03-13 2017-04-13 プロセナ バイオサイエンシーズ リミテッド 多発性硬化症の併用治療
CN106459042B (zh) * 2014-04-02 2019-06-28 英特穆恩公司 抗纤维化吡啶酮类
US10246451B2 (en) * 2017-04-26 2019-04-02 Aviara Pharmaceuticals, Inc. Propionic acid derivatives and methods of use thereof
US10875875B2 (en) * 2017-04-26 2020-12-29 Aviara Pharmaceuticals, Inc. Propionic acid derivatives and methods of use thereof
MX2019012699A (es) * 2017-04-28 2020-12-11 Texas Childrens Hospital Nanoparticulas dirigidas.
KR20260007293A (ko) * 2018-02-02 2026-01-13 제넨테크, 인크. 약제학적 화합물, 이의 염, 이의 제형, 그리고 이의 제조 방법 및 사용 방법
HUE070112T2 (hu) 2018-10-30 2025-05-28 Gilead Sciences Inc 3-(Kinolin-8-il)-1,4-dihidropirido[3,4-d]pirimidin-2,4-dion-származékok mint alpha4beta7 integrin gátlók gyulladásos betegségek kezelésére
JP7189369B2 (ja) 2018-10-30 2022-12-13 ギリアード サイエンシーズ， インコーポレイテッド アルファ４β７インテグリンの阻害のための化合物
EP3873900B1 (de) 2018-10-30 2025-01-08 Gilead Sciences, Inc. Imidazo[1,2-a]pyridin-derivate als alpha4beta7 integrin-inhibitoren zur behandlung von entzündlichen erkrankungen
CN112996786B (zh) 2018-10-30 2024-08-20 吉利德科学公司 用于抑制α4β7整合素的化合物
JP7491996B2 (ja) 2019-08-14 2024-05-28 ギリアード サイエンシーズ， インコーポレイテッド α４β７インテグリンの阻害のための化合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2614189A1 (de) * 1976-04-02 1977-10-20 Hoechst Ag Therapeutisch wirksame ureido- und semicarbazido-derivate des tiazols und verfahren zu ihrer herstellung
US5220017A (en) * 1991-04-10 1993-06-15 Merck & Co., Inc. Cholecystokinin antagonists
DE69425431T2 (de) * 1993-03-31 2001-02-08 G.D. Searle & Co., Chicago 1-amdinophenyl-pyrrolidone/piperidinone als blutblättchen-aggregations inhibitoren
AU672699B2 (en) * 1993-06-30 1996-10-10 Sankyo Company Limited Amide and urea derivatives having anti-hypercholesteremic activity, their preparation and their therapeutic uses
US5770573A (en) * 1993-12-06 1998-06-23 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
JPH07304755A (ja) * 1994-05-12 1995-11-21 Yamanouchi Pharmaceut Co Ltd 縮合ジアゼピン誘導体
US5610296A (en) * 1994-12-05 1997-03-11 G. D. Searle & Co. Process for the preparation of amidino phenyl pyrrolidine beta-alanine urea analogs
US6306840B1 (en) * 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
PT912901E (pt) * 1996-05-15 2002-04-29 Searle & Co Metedo e reagentes para monitorizacao dos niveis sanguineos de compostos antiagregantes plaquetares
WO1998011896A1 (en) * 1996-09-18 1998-03-26 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardiovascular disease
US6025358A (en) * 1998-06-11 2000-02-15 G. D. Searle & Co. Double prodrugs of potent GP IIb/IIIa antagonists
HK1040076A1 (zh) * 1998-09-21 2002-05-24 希雷生物化学有限公司 作为整联蛋白抑制剂的喹嗪酮

Also Published As

Publication number Publication date
IL146311A0 (en) 2002-07-25
TR200103178T2 (tr) 2002-05-21
WO2000067746A1 (en) 2000-11-16
CY1107438T1 (el) 2012-12-19
ATE383153T1 (de) 2008-01-15
JP5132855B2 (ja) 2013-01-30
AU5267900A (en) 2000-11-21
CA2373360C (en) 2011-09-06
NO324421B1 (no) 2007-10-08
SK16082001A3 (sk) 2002-04-04
MXPA01011340A (es) 2003-08-01
HK1045805A1 (en) 2002-12-13
CZ303312B6 (cs) 2012-07-25
NZ515248A (en) 2004-01-30
NO20015418D0 (no) 2001-11-06
NO20015418L (no) 2001-12-21
EP1176956A4 (de) 2002-08-28
CA2373360A1 (en) 2000-11-16
ZA200108774B (en) 2003-01-24
SK286696B6 (sk) 2009-03-05
CZ20013963A3 (cs) 2002-04-17
ES2296625T3 (es) 2008-05-01
RO122246B1 (ro) 2009-03-30
DK1176956T3 (da) 2008-05-26
SI20744B (sl) 2009-08-31
RU2263109C2 (ru) 2005-10-27
PL351396A1 (en) 2003-04-07
SI20744A (sl) 2002-06-30
WO2000067746A9 (en) 2002-08-29
DE60037726T2 (de) 2009-03-05
TR200201920T2 (tr) 2002-09-23
WO2000067746A8 (en) 2002-02-28
IL146311A (en) 2011-10-31
JP2002544161A (ja) 2002-12-24
IN2001KN01110A (de) 2015-06-05
EP1176956B1 (de) 2008-01-09
EP1176956A1 (de) 2002-02-06
PL205322B1 (pl) 2010-04-30

Similar Documents

Publication Publication Date Title
DE60037726D1 (de) Carbonsäurederivate die die bindung von integrinen an ihre rezeptoren hemmen
ATE420876T1 (de) Propansäurederivate die die bindung von integrinen an ihre rezeptoren hemmen
DE69942610D1 (de) Die bindung von integrinen zu deren rezeptoren verhindernde verbindungen
ATE547406T1 (de) Carbonsäurederivate, die die bindung von integrinen an ihre rezeptoren hemmen
DE60014369D1 (de) Propansäurederivate, die die bindung von integrinen an ihre rezeptoren behindern
CA2361285A1 (en) Propanoic acid derivatives that inhibit the binding of integrins to their receptors

Legal Events

Date Code Title Description
8364 No opposition during term of opposition